Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Debt to Equity (2018 - 2022)

Lipocine (LPCN) has disclosed Debt to Equity for 5 consecutive years, with $0.03 as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Debt to Equity fell 68.98% year-over-year to $0.03, compared with a TTM value of $0.03 through Mar 2022, down 68.98%, and an annual FY2021 reading of $0.05, down 86.08% over the prior year.
  • Debt to Equity was $0.03 for Q1 2022 at Lipocine, down from $0.05 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.14 in Q4 2019 and bottomed at $0.03 in Q1 2022.
  • Average Debt to Equity over 5 years is $0.58, with a median of $0.6 recorded in 2018.
  • The sharpest move saw Debt to Equity increased 28.22% in 2020, then crashed 88.38% in 2021.
  • Year by year, Debt to Equity stood at $1.09 in 2018, then rose by 4.52% to $1.14 in 2019, then plummeted by 67.95% to $0.36 in 2020, then plummeted by 86.08% to $0.05 in 2021, then tumbled by 31.08% to $0.03 in 2022.
  • Business Quant data shows Debt to Equity for LPCN at $0.03 in Q1 2022, $0.05 in Q4 2021, and $0.1 in Q3 2021.